Concepedia

Lelanie Van Zyl

LV

2

Publications

141

Citations

2

H-Index

2021

Active since

Affiliations

Janssen (Belgium)(Current)

ViiV Healthcare (United Kingdom)

University of Nebraska Medical Center

GlaxoSmithKline (Canada)

Fundación para la Investigación, Docencia y Prevención del Cáncer

Lelanie Van Zyl is an author at Janssen (Belgium) specializing in hiv/aids counselling, drug resistance, and drug discovery.

Top concepts

Publications per year

2021–2022

2

Publications

2

Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment

Susan Swindells, Thomas A. Lutz, Lelanie Van Zyl et al. · AIDS · 2021 · 92 citations · Full text

, , +18

Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment.

Susan Swindells, Thomas A. Lutz, Lelanie Van Zyl et al. · AIDS · 2022 · 49 citations · Full text

Rows per page

1–2 of 2